| Mark A Shawnik, DO | |
|
500 J Clyde Morris Blvd, Newport News, VA 23601-1929 | |
| (757) 594-2000 | |
| Not Available |
| Full Name | Mark A Shawnik |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 500 J Clyde Morris Blvd, Newport News, Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265459861 | NPI | - | NPPES |
| 1265459861 | Medicaid | VA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 00-36265 (North Carolina) | Secondary |
| 207P00000X | Emergency Medicine | 0102-037036 (Virginia) | Primary |
| Entity Name | Washington County Hospital District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659321560 PECOS PAC ID: 4880599844 Enrollment ID: O20031209000278 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a biological therapy with a mechanism of action other than tumor necrosis factor alpha (TNF-alpha) inhibition for the treatment of moderate to severe ulcerative colitis, would earn a 25 percent patient share according to surveyed U.S. gastroenterologists. Similarly, in Europe, such an agent would also earn 25 percent patient share according to surveyed European gastroenterologists.
Researchers have developed a chip capable of simulating a tumor's "microenvironment" and plan to use the new system to test the effectiveness of nanoparticles and drugs that target cancer.
After Mimivirus, Mamavirus and the virophage, the group of giant viruses now has a new member called Marseillevirus. Discovered in an amoeba by the team led by Didier Raoult at the Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes research group (CNRS/Université Aix-Marseille 2), a description of this new virus was published this week on the website of the Proceedings of the National Academy of Sciences (PNAS).
Today, the U.S. Food and Drug Administration released the agency's first Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan. This action plan describes a multi-pronged approach to advance the Agency's oversight of AI/ML-based medical software.
› Verified 8 days ago
| Entity Name | Integritas Emergency Physician Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790128817 PECOS PAC ID: 7113167446 Enrollment ID: O20130710000760 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a biological therapy with a mechanism of action other than tumor necrosis factor alpha (TNF-alpha) inhibition for the treatment of moderate to severe ulcerative colitis, would earn a 25 percent patient share according to surveyed U.S. gastroenterologists. Similarly, in Europe, such an agent would also earn 25 percent patient share according to surveyed European gastroenterologists.
Researchers have developed a chip capable of simulating a tumor's "microenvironment" and plan to use the new system to test the effectiveness of nanoparticles and drugs that target cancer.
After Mimivirus, Mamavirus and the virophage, the group of giant viruses now has a new member called Marseillevirus. Discovered in an amoeba by the team led by Didier Raoult at the Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes research group (CNRS/Université Aix-Marseille 2), a description of this new virus was published this week on the website of the Proceedings of the National Academy of Sciences (PNAS).
Today, the U.S. Food and Drug Administration released the agency's first Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan. This action plan describes a multi-pronged approach to advance the Agency's oversight of AI/ML-based medical software.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark A Shawnik, DO Po Box 601783, Charlotte, NC 28260-1783 Ph: (866) 916-5259 | Mark A Shawnik, DO 500 J Clyde Morris Blvd, Newport News, VA 23601-1929 Ph: (757) 594-2000 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a biological therapy with a mechanism of action other than tumor necrosis factor alpha (TNF-alpha) inhibition for the treatment of moderate to severe ulcerative colitis, would earn a 25 percent patient share according to surveyed U.S. gastroenterologists. Similarly, in Europe, such an agent would also earn 25 percent patient share according to surveyed European gastroenterologists.
Researchers have developed a chip capable of simulating a tumor's "microenvironment" and plan to use the new system to test the effectiveness of nanoparticles and drugs that target cancer.
After Mimivirus, Mamavirus and the virophage, the group of giant viruses now has a new member called Marseillevirus. Discovered in an amoeba by the team led by Didier Raoult at the Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes research group (CNRS/Université Aix-Marseille 2), a description of this new virus was published this week on the website of the Proceedings of the National Academy of Sciences (PNAS).
Today, the U.S. Food and Drug Administration released the agency's first Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan. This action plan describes a multi-pronged approach to advance the Agency's oversight of AI/ML-based medical software.
› Verified 8 days ago
Dr. Adrian Dews Sr., D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2 Bernadine Drive, Emergency Dept, Newport News, VA 23602 Phone: 757-886-6271 Fax: 757-886-6121 | |
Eric V. Obie, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 12997 Warwick Blvd, Michumi, Pllc Dba Md Express, Newport News, VA 23602 Phone: 757-369-9446 Fax: 757-369-9554 | |
Dr. Paul D Osborne, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 11803 Jefferson Ave, Suite 120, Newport News, VA 23606 Phone: 757-594-1060 Fax: 757-594-1066 | |
Dr. Matthew Stephen Berniard, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 500 J Clyde Morris Blvd, Newport News, VA 23601 Phone: 757-612-8154 Fax: 757-594-2196 | |
Elena Cuticelli Garrett, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 500 J Clyde Morris Blvd, Newport News, VA 23601 Phone: 757-594-2983 | |
Christopher A Haas, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 500 J Clyde Morris Blvd, Newport News, VA 23601 Phone: 757-594-2000 | |
Troy Dean Myers, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 500 J Clyde Morris Blvd, Newport News, VA 23601 Phone: 757-594-2083 |